AIM ImmunoTech Reports Q2 Losses Amid Ongoing Trials, Revenue Down to $25k.

AIM ImmunoTech Inc. reported a decrease in total revenues to $25,000 from $50,000 YoY and a net loss of $2.8 million, up from $1.8 million in the previous year. The company is focused on clinical trials for Ampligen in treating pancreatic cancer and exploring its antiviral properties. Despite financial challenges, AIM ImmunoTech remains committed to advancing its research and development efforts. Management expresses optimism about future clinical trials and potential regulatory approvals.